Table 1 Clinicopathological features of hepatocellular carcinomas in cohort 2 according to the CAIX protein expression status
Clinicopathologic features | CAIX positive n=13 (15%) | CAIX negative n=72 (85%) | P-value |
|---|---|---|---|
Age (year) | 52 (45–56) | 54 (50–60) | 0.067 |
Gender (male/female) | 10 (77%)/3 (23%) | 59 (82%)/13 (18%) | 0.670 |
Etiology (hepatitis B/hepatitis C/alcohol/unknown) | 11 (85%)/1 (8%)/1 (8%)/0 (0%) | 59 (82%)/8 (11%)/4 (6%)/1 (1%) | 0.941 |
Cirrhosis | 13 (100%) | 70 (97%) | 1.000 |
Serum aspartate transaminase (IU/l) | 42 (35–75) | 46 (35–68) | 0.779 |
Serum alanine transaminase (IU/l) | 31 (13–58) | 32 (20–40) | 0.883 |
Serum albumin (g/dl) | 3.0 (2.6–3.8) | 3.3 (2.8–3.6) | 0.399 |
Serum platelet (1000/μl) | 66 (41–101) | 79 (54–118) | 0.173 |
Serum alpha-fetoprotein (IU/ml) | 29.0 (2.9–246.2) | 10.9 (4.8–60.9) | 0.502 |
Serum PIVKA-II (AU/ml)a | 76.0 (24.0–402.3) | 37.5 (18.3–96.0) | 0.131 |
Tumor pathology | |||
 Diameter of largest tumor (cm) | 3.0 (2.3–3.5) | 2.2 (1.6–3.5) | 0.319 |
 Total tumor diameter (cm) | 3.5 (2.4–5.5) | 3.6 (2.4–6.4) | 0.665 |
 Differentiation (Edmonson–Steiner grades I/II/III) | 1 (8%)/11 (85%)/1 (8%) | 27 (38%)/40 (56%)/5 (7%) | 0.104 |
 Capsule formation (absent/partial/complete) | 0 (0%)/9 (69%)/4 (31%) | 22 (31%)/32 (44%)/18 (25%) | 0.063 |
 Microvascular invasion | 8 (62%) | 13 (18%) | 0.002b |
 Number of the lesion (1/2 or 3/≥4) | 6 (46%)/6 (46%)/1 (8%) | 23 (32%)/35 (49%)/14 (19%) | 0.466 |
 Milan status (in/out) | 9 (69%)/4 (31%) | 48 (67%)/24 (33%) | 1.000 |
 K19 protein expression | 7 (54%) | 8 (11%) | 0.001b |
 EpCAM protein expression | 5 (39%) | 10 (14%) | 0.048b |
